Andrés Felipe Buitrago

Andrés Felipe Buitrago

Auto-generated profile, based on publicly available information

Andrés Felipe Buitrago

Departamento de Cardiología, Fundación Santa Fe de Bogotá, Bogotá, Colombia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2024 in Biomédica
Verified
Journal Article
Open access
PDF file
LELuis Echeverria
Luis Echeverria
CSClara Saldarriaga
Clara Saldarriaga
SCSebastián Campbell-Quintero
Sebastián Campbell-Quintero
LMLisbeth Natalia Morales-Rodríguez
Lisbeth Natalia Morales-Rodríguez
JLJuan David Lopez
Juan David Lopez
RGRECOLFACA research group
RECOLFACA research group
Introduction. Heart failure and type 2 diabetes mellitus are critical public health issues.Objective. To characterize the risk factors for mortality in patients with heart failure and type 2 diabetes mellitus from a large registry in Colombia and to evaluate the potential effect modifications by type 2 diabetes mellitus over other risk factors.Materials and methods. Heart failure patients with and without type 2 diabetes mellitus enrolled in the Registro Colombiano de Falla Cardíaca (RECOLFACA) were included. RECOLFACA enrolled adult patients with heart failure diagnosis from 60 medical centers in Colombia during 2017-2019. The primary outcome was all-cause mortality. Survival analysis was performed using adjusted Cox proportional hazard models.Results. A total of 2514 patients were included, and the prevalence of type 2 diabetes mellitus was 24.7% (n = 620). We found seven independent predictors of short-term mortality for the general cohort, chronic obstructive pulmonary disease, sinus rhythm, triple therapy, nitrates use, statins use, anemia, and hyperkalemia. In the type 2 diabetes mellitus group, only the left ventricle diastolic diameter was an independent mortality predictor (HR = 0.96; 95% CI: 0.93-0.98). There was no evidence of effect modification by type 2 diabetes mellitus on the relationship between any independent predictors and all-cause mortality. However, a significant effect modification by type 2 diabetes mellitus between smoking and mortality was observed.Conclusions. Patients with type 2 diabetes mellitus had higher mortality risk. Our results also suggest that type 2 diabetes mellitus diagnosis does not modify the effect of the independent risk factors for mortality in heart failure evaluated. However, type 2 diabetes mellitus significantly modify the risk relation between mortality and smoking in patients with heart failure.

2 September 2025 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
BCBrayan Daniel Cordoba-Melo
Brayan Daniel Cordoba-Melo
SSSebastián Seni-Molina
Sebastián Seni-Molina
JAJuan Pablo Arango-Ibanez
Juan Pablo Arango-Ibanez
MAMilton René Ayala
Milton René Ayala
JTJosé Fidel Tatis-Méndez
José Fidel Tatis-Méndez
OGOn Behalf of EDHIPO MARCA Research Group
On Behalf of EDHIPO MARCA Research Group
Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, with dyslipidemia playing a key role in its progression. Despite advances in lipid-lowering therapy (LLT), LDL-C (Low-Density Lipoprotein Cholesterol) goal achievement remains suboptimal. This study evaluated LDL-C goal attainment in Colombian patients with very high cardiovascular risk (CVR) due to coronary artery disease (CAD) following ESC/EAS guidelines updates. EDHIPO MARCA (Evaluación De adherencia a la terapia HIPOlipemiante en pacientes de Muy Alto Riesgo CArdiovascular) is a retrospective, multicenter study assessing LDL-C goal achievement in patients with CAD. Data were collected from previous coronary angiogram reports and medical records across 11 Colombian healthcare institutions with certified interventional cardiology services. Patients with CAD who had at least one follow-up LDL-C measurement and an LLT prescription within 12 months post-angiogram were included. LDL-C goal attainment was assessed across three periods—2011–2012, 2016–2017, and 2021–2022—corresponding to the updates of ESC/EAS guidelines (2011, 2016, and 2019, respectively). The LDL-C goals were <70 mg/dL for the first two periods and <55 mg/dL for the most recent one. LDL-C was measured or estimated using the Friedewald equation. Descriptive analyses were performed. A total of 1,788 patients were included, with a median age of 66 years (IQR: 59–74), and 70.7% were male. Hypertension (67.5%) and overweight (40.8%) were the most common comorbidities. At discharge, statins were prescribed in 84.1% (95% CI: 82.4–85.8%) of patients, increasing to 99.1% (95% CI: 98.6–99.5%) at the end of follow-up (median 6.8 months); PCSK9 inhibitors were prescribed in 1.5%, exclusively in 2019. At the end of follow-up, 36.6% (95% CI: 34.3%, 38.8%) achieved LDL-C goals. By guideline period, goal attainment was 12.1% (95% CI: 5.4%, 18.8%) in 2011, 42.3% (95% CI: 37.9%, 46.8%) in 2016, and 36.2% (95% CI: 33.5%, 38.9%) in 2019. By number of follow-ups, LDL-C goal achievement increased from 32.9% (1 follow-up) to 44.0% (4 follow-ups). Despite widespread LLT use, LDL-C target achievement remains suboptimal. Frequent follow-up and greater use of combination therapy beyond statins may be essential to improve lipid control in very high CVR patients.

28 September 2026 in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
Verified
Journal Article
Open access
PDF file
JFJuan Francisco Figueroa
Juan Francisco Figueroa
CSClara Saldarriaga
Clara Saldarriaga
ABAndrés Buitrago
Andrés Buitrago
APAlexandra Pérez
Alexandra Pérez
ÁHÁngela Herrera
Ángela Herrera
JGJuan Esteban Gómez-Mesa
Juan Esteban Gómez-Mesa
El infarto agudo de miocardio (IAM) representa un desafío prioritario de salud pública en Latinoamérica y Colombia, caracterizado por una elevada carga de morbimortalidad. Esta revisión narrativa analiza la situación actual del IAM a nivel regional, destacando las profundas desigualdades socioeconómicas, los sistemas de salud fragmentados y la transición epidemiológica con alta prevalencia de factores de riesgo como hipertensión, diabetes y obesidad. En la región, el acceso a la reperfusión en el IAM con elevación del ST (IAMCEST) es heterogéneo: la proporción de pacientes tratados con intervención coronaria percutánea primaria (ICPp) varía ampliamente según el país, el centro y la población estudiada; la fibrinólisis se utiliza poco y con frecuencia no se cumplen los tiempos de reperfusión recomendados por las guías. En Colombia, aunque existen guías clínicas avanzadas y se ha descrito una alta adherencia farmacológica en centros de alta complejidad, persisten barreras críticas como la disparidad en el acceso entre zonas urbanas y rurales, la concentración de unidades de hemodinamia en grandes ciudades y limitaciones en el diagnóstico oportuno en instituciones de baja complejidad. Adicionalmente, se identifican limitaciones en la prevención secundaria y el seguimiento posterior al egreso hospitalario. Los datos disponibles proceden mayoritariamente de registros hospitalarios y estudios observacionales heterogéneos, lo que limita su generalización. A partir de este documento, se propone fortalecer las redes de telemedicina, implementar protocolos de atención estandarizados, optimizar las redes de referencia y contrarreferencia, y desarrollar registros nacionales para monitorear resultados y cerrar las brechas en la atención integral del IAM, con el fin de mejorar la equidad y los desenlaces clínicos en la región.